Last reviewed · How we verify
MHAA4549A
At a glance
| Generic name | MHAA4549A |
|---|---|
| Sponsor | Genentech, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults (PHASE2)
- A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection (PHASE2)
- A Study of High Dose MHAA4549A in Healthy Volunteers (PHASE1)
- A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model (PHASE2)
- A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MHAA4549A CI brief — competitive landscape report
- MHAA4549A updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI